Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Evopoint Biosciences Inc.
Study ID
NCT07707674
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • XNW28012 — DRUG
    XNW28012 is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Tissue Factor (TF) and a topoisomerase I inhibitor.

Study Details

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer

Key Dates

First listed
Jul 16, 2026
Start date
Jul 30, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: XNW28012 2.0 mg/kg dose level
    XNW28012 2.0 mg/kg, IV, every 3 weeks (Q3W; 21-day cycles).
  • Experimental: XNW 28012 2.4 mg/kg dose level
    XNW28012 2.4 mg/kg, IV, every 3 weeks (Q3W; 21-day cycles).

Primary Outcome Measure

Incidence of Adverse Events (AEs) [ Time Frame: From the first dose of study treatment through 30 days after the last dose of study treatment. ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
Karmanos Cancer InstituteDetroitMichigan48201
Wasif Saif, MD
[email protected]
+1 (800) 527-6266
New Patient Referrals
START - MidwestGrand RapidsMichigan49546
New Patient Referrals
[email protected]
+1 (616) 954-5554
START - New York Long IslandLake SuccessNew York10042
New Patient Referrals
[email protected]
+1 (363) 207-5160
Cleveland Clinic FoundationClevelandOhio44195
Cancer Care Line
[email protected]
+1 (216) 444-7923
Oklahoma University Health Sciences CenterOklahoma CityOklahoma73104
Coordinator Clinicial Operations Director
[email protected]
+1 (405) 271-1112
SCRI Oncology PartnersNashvilleTennessee37203
New Patient Referrals
[email protected]
+1 (615) 329-7640
SCRI at Mary CrowleyDallasTexas75230
New Patient Referrals
[email protected]
+1 (972) 566-3000
START - San AntonioSan AntonioTexas78229
New Patient Referrals
[email protected]
+1 (210) 593-5250

Find similar trials in Detroit, MI

By research site
Karmanos Cancer Institute· Detroit, MISTART - Midwest· Grand Rapids, MISTART - New York Long Island· Lake Success, NYCleveland Clinic Foundation· Cleveland, OHOklahoma University Health Sciences Center· Oklahoma City, OKSCRI Oncology Partners· Nashville, TN

Related Studies